Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IORT in newly diagnosed glioblastoma
NCT02685605Phase 3Active, not recruiting
- Sponsor
- Universitätsmedizin Mannheim
- Start
- Dec 2016
- Primary completion
- Nov 2025
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in glioblastoma multiforme (GBM), sponsored by Universitätsmedizin Mannheim. Primary endpoint: Progression-Free Survival at 24 months. Started Dec 2016; status: active, not recruiting.
02
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02685605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685605.